Kiora Pharmaceuticals price target lowered to $2 from $7 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Kiora Pharmaceuticals to $2 from $7 and keeps a Buy rating on the shares post the Q2 report. As a result of this focus on KIO-301, continued development of anterior segment applications for KIO-101 and KIO-201 are dependent on potential strategic partnerships, the analyst tells investors in a research note.